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Previous studies have shown that the M72/AS01E candidate tuberculosis vaccine is immunogenic with a
clinically acceptable safety proﬁle in healthy and Mycobacterium tuberculosis-infected adults. This phase
II, observer-blind, randomised study compared the safety, reactogenicity, and immunogenicity of M72/
AS01E in 3 cohorts: tuberculosis-naïve adults (n ¼ 80), adults previously treated for tuberculosis (n ¼ 49),
and adults who have completed the intensive phase of tuberculosis treatment (n ¼ 13).
In each cohort, 18e59-year-old adults were randomised (1:1) to receive two doses of M72/AS01E
(n ¼ 71) or placebo (n ¼ 71) and followed-up until six months post-dose 2. Safety and reactogenicity
were assessed as primary objective.
Recruitment in the study ended prematurely because of a high incidence of large injection site
redness/swelling reactions in M72/AS01E-vaccinated adults undergoing tuberculosis treatment. No
additional clinically relevant adverse events were observed, except one possibly vaccine-related serious
adverse event (hypersensitivity in a tuberculosis-treated-M72/AS01E participant). Robust and persistent
M72-speciﬁc humoral and polyfunctional CD4þ T-cell-mediated immune responses were observed post-
M72/AS01E vaccination in each cohort. In conclusion, the M72/AS01E vaccine was immunogenic in adults
previously or currently treated for tuberculosis, but further analyses are needed to explain the high local
reactogenicity in adults undergoing tuberculosis treatment.
ClinicalTrials.gov: NCT01424501
© 2016 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) remains one of the world's deadliest commu-
nicable diseases. It has been estimated that one third of the worldg to protocol; BCG, Bacille
CI, conﬁdence interval; CMI,
munosorbent assay; EU/mL,
centration; HIV, human im-
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ublished by Elsevier Ltd. This is anpopulation is infected withMycobacterium tuberculosis, resulting in
approximately 9.6 million new cases and 1.5 million deaths in 2014
[1]. Infected individuals can be clinically classiﬁed into patientswith
active TB disease and individuals with latent TB infections (in the
absence of clinical symptoms of disease) [2e5]. Latent TB infections
include a spectrum of individuals at widely differing risk of devel-
oping active TB [6]._ENREF_2 The vast majority of individuals with
latent TB infections never develop active disease and remain
asymptomatic, but that group acts as a reservoir for new cases.
Moreover, it can take months to years to develop symptomatic and
bacteriologically detectable TB. During this period, asymptomatic
states with manifestations and duration dependent on the host
immune response remain mostly unidentiﬁed.
The Bacille Calmette-Guerin (BCG) is the only licensed TB vac-
cine, but varying estimates of its efﬁcacy in preventing pulmonaryopen access article under the CC BY-NC-ND license (http://creativecommons.org/
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prophylactic and immunotherapeutic vaccines against TB disease
are under development, including the prophylactic M72/AS01E
vaccine [8,9]. The M72/AS01E vaccine is composed of the M72 an-
tigen, which is a recombinant fusion protein derived from the
M. tuberculosis proteins Mtb32A and Mtb39A, and the AS01 Adju-
vant System [10]. Previous studies have shown that this vaccine has
a clinically acceptable safety proﬁle, and induces humoral immune
responses and cell-mediated immunity (CMI) in healthy, human
immunodeﬁciency virus (HIV)-infected and M. tuberculosis-infec-
ted adults, and in BCG-vaccinated toddlers [10e15].
In this study, we compared for the ﬁrst time the safety, reac-
togenicity, and immunogenicity of M72/AS01E in adults currently
receiving treatment for TB disease and adults with previous history
of successfully treated pulmonary TB disease. Adults receiving
treatment for TB disease, who had completed the intensive phase of
treatment, were included in this study as a surrogate for individuals
with latent TB evolving to active but still undiagnosed overt TB
disease who are hence not yet treated for TB. Even if the tools were
available to identify patients with latent TB evolving to active TB
disease, it is unlikely that these patients would be included in
prophylactic clinical trial settings, as once identiﬁed and diagnosed,
patients with active TB should be offered antibiotic treatment.
Although effective TB vaccines are not available currently, if such
vaccines are included in national immunisation programmes in the
future, patients with latent TB evolving to active TB disease could
inadvertently be vaccinated and hence pose a theoretical safety
concern. Adults with a history of active TB disease who received
previous treatment were also included in the present study as they
represent a group of patients at risk of relapse due to re-infection or
reactivation, who would greatly beneﬁt from a vaccine against TB
[16].
2. Methodology
2.1. Study design and ethics
This was a phase II, observer-blind, randomised, controlled
study conducted initially in four centres in Taiwan and subse-
quently in two centres in Estonia. In Taiwan, participants were
enrolled through the National Taiwan University Hospital (NTUH)
and other afﬁliated institutions. The NTUH is the biggest medical
centre in Taiwan and conducts over 150 clinical trials per year. In
Estonia, participants were enrolled through the Innomedica OÜ
centre in Tallin and through Tartu University Hospital Lung Clinic.
The study started on November 14, 2011. However, following the
identiﬁcation of a safety signal, enrolment and further vaccination
were terminated by the Sponsor on December 16, 2013. All the
enrolled participants continued the study until the end, and the last
visit occurred on April 10, 2014.
The study included three cohorts: adults with smear- or culture-
conﬁrmed pulmonary TB disease who had completed the intensive
phase of treatment, i.e. had documented treatment for pulmonary
TB disease ongoing for 2e4 months prior to vaccination (TB-
treatment cohort); adults with previous history of successfully
treated pulmonary TB disease at least one year prior to vaccination
and with no active pulmonary disease on chest X-ray (TB-treated
cohort); and adults who had no active pulmonary disease as indi-
cated by chest X-ray, no signs and symptoms of TB disease, and no
history of chemoprophylaxis or treatment for TB (TB-naïve cohort).
Chest radiographs were performed for all participants before the
ﬁrst vaccination. For the participants from the TB-naïve cohort, a
Mantoux test (tuberculin puriﬁed protein derivative (PPD) RT 23
SSI; Statens Serum Institute, Copenhagen, Denmark) was per-
formed at least 2 weeks before ﬁrst vaccination.Participants from each cohort were randomised (1:1) using a
block randomisation (MATEX; SAS Institute Inc.) in two parallel
groups to receive two doses of the M72/AS01E vaccine or a placebo.
The treatment allocation at the investigator sites was performed
using a central Randomisation System on Internet (SBIR, GSK
Vaccines) with a minimisation algorithm. The ﬁrst dose of vaccine
was administered to a safety subset of 12 participants in the TB-
treated cohort. The vaccination continued in the TB-treated
cohort and started in the TB-treatment cohort if no safety issues
were observed during the protocol-deﬁned review of data that was
performed on the safety subset after the ﬁrst vaccination. The same
process was repeated after the second vaccine dose administration.
Further enrolment and vaccination would be stopped if the
following holding rules were met: i) vaccination in a particular
cohort would be put on hold pending review of data if at least two
vaccinated participants in that cohort were withdrawn for a
vaccine-related adverse event (AE) by the investigator during the
safety review time period, and ii) vaccination in all cohorts would
be put on hold pending review of data for a fatal or life-threatening
serious AE (SAE) judged by the investigator to be related to vacci-
nation at any time during the study, or for an anaphylactic shock
reaction following vaccination. For participants in the TB-naïve
cohort, vaccination proceeded without any scheduled safety
review.
The study protocol and informed consent forms were reviewed
and approved prior to initiation of the study by national Ethics
Committees in Taiwan and subsequently in Estonia. Written
informed consent was obtained from each participant prior to
enrolment. The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice. The trial was
registered with ClinicalTrials.gov (NCT01424501). A summary of
the protocol is available at http://www.gsk-clinicalstudyregister.
com (GSK study ID 114886).
2.2. Study population and vaccination
Study participants were adults aged 18e59 years at ﬁrst vacci-
nation, who were seronegative for HIV-1 and HIV-2 antibodies, had
no history of extra-pulmonary TB, and had provided written
informed consent. Participants in the TB-treatment cohort had
documented treatment for pulmonary TB ongoing for 2e4 months
prior to vaccination, were enrolled after their ﬁrst check-up visit
following the active phase of treatment, and received TB treatment
independently of the study (by the TB centre recruiting the par-
ticipants or through referral to a TB centre). In both countries, the
World Health Organisation guidelines on the treatment of TB were
followed, and regimens that included isoniazid, rifampicin,
ethambutol and pyrazinamide were used for at least 2 months in
the intensive phase of the disease, followed by isoniazid, rifampicin
and ethambutol in the continuous phase for 4 months [17]. Par-
ticipants who had successfully completed treatment for TB disease
at least 1 year before the ﬁrst vaccination were enrolled in the TB-
treated cohort.
Participants were excluded if they had used an investigational
product within 30 days prior to the study or planned to use an
investigational product during the study, had a history of admin-
istration of experimental TB vaccines, were immunosuppressed
(chronic administration of immunosuppressants or other immune-
modifying drugs within 6 months prior to the ﬁrst vaccine dose, or
any conﬁrmed or suspected immunosuppressive or immunodeﬁ-
cient condition based on medical history and physical examina-
tion), had received immunoglobulins or blood products within 3
months before administration of the ﬁrst dose of the study vaccine
or had planned administration during the study, or had any chronic
drug therapy that had to be continued during the study period and
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were also exclusion criteria. Participants in the TB-treatment cohort
who failed to convert at the end of the second month of treatment
(persistent sputum or culture positivity) were also excluded from
the study.
M72/AS01E consisted of a 0.5 ml dose containing 10 mg M72
reconstituted with the AS01E, a GSK proprietary Adjuvant System,
which contains 25 mg MPL (3-O-desacyl-40-monophosphoryl lipid
A; produced by GSK), 25 mg QS-21 (Quillaja saponaria Molina,
fraction 21; licensed by GSK from Antigenics Inc., a wholly owned
subsidiary of Agenus Inc., a Delaware, USA corporation), and lipo-
somes. The placebo consisted of physiological saline. Each enrolled
participant was vaccinated at baseline (Day 0) and at Day 30 by
intramuscular injection into the deltoid muscle of the non-
dominant arm.
2.3. Study objectives
The primary objective of this study was to assess the safety and
reactogenicity of M72/AS01E in adults who were receiving treat-
ment for TB disease, had received treatment for TB disease, or never
had TB. Secondary objectives included the assessment of the
immunogenicity of M72/AS01E in the same populations.
2.4. Safety and reactogenicity evaluation
Participants were provided with diary cards to report AEs
occurring within 7 days after each vaccination. Solicited local AEs at
the injection site included pain, redness, and swelling, whereas
solicited general AEs included fatigue, fever (axillary temperature
37.5 C), gastrointestinal symptoms, headache, malaise, and
myalgia. Unsolicited AEs were recorded during a 30-day follow-up
period after each vaccination. Grade 3 AEs were deﬁned as AEs
preventing normal activity, redness or swelling >100 mm in
diameter, or an axillary temperature >39.5 C.
SAEs were collected during the entire study period (until 210
days post-dose 1). A SAE was deﬁned as any untoward medical
occurrence that resulted in death, was life-threatening, required
hospitalisation or prolongation of existing hospitalisation, resulted
in disability/incapacity, or was a congenital anomaly/birth defect in
the offspring of a study participant.
Changes in biochemical and haematological parameters (com-
plete blood count, creatinine, bilirubin, alanine aminotransferase
and aspartate aminotransferase) were recorded on the days of
vaccination (Day 0 and Day 30), at Days 7, 37 and 60, and were
graded according to the Food and Drug Administration toxicity
scale [18].
2.5. Immunogenicity evaluation
Humoral immune responses and CMI were evaluated on blood
samples collected at Days 0, 30, 60 and 210. For CMI, two additional
blood samples were collected at Days 7 and 37.
The humoral immune response in terms of M72-speciﬁc anti-
body concentrations was measured by enzyme linked immuno-
sorbent assay (ELISA) with a cut-off of 2.8 ELISA units per millilitre
(EU/ml), as previously described [11].
Intracellular cytokine staining (ICS), as previously described
[10,11,14,19], was used to detect CD4þ and CD8þ T-cells expressing
interferon-gamma (IFN-g), interleukin (IL)-2, tumour necrosis
factor-alpha (TNF-a), CD40-ligand (CD40L), IL-17 and IL-13 after
in vitro stimulation. ICS was performed on thawed peripheral blood
mononuclear cells (PBMCs) stimulated with pools of overlapping
peptides covering the entire M72 sequence. ICS results were pre-
sented as background-subtracted percentages of M72-speciﬁcCD4þ/CD8þ T-cells per million cells expressing 2 immune
markers among IFN-g, IL-2, TNF-a, CD40L, IL-17 and IL-13, and
percentages of M72-speciﬁc, PPD-speciﬁc and CFP10-speciﬁc CD4þ/
CD8þ T-cells per million cells expressing any combination of the
different immune markers. Of note, the ICS assays were run with 6
cytokines, covering the 4 cytokines as planned in the secondary
endpoint of the study protocol, while 2 cytokines (IL-17 and IL-13)
were included as exploratory markers that were not planned in the
protocol nor in the statistical analysis plan. The results with 4 cy-
tokines (IFN-g, IL-2, TNF-a, CD40L) were deduced during the sta-
tistical analysis. Exploratory analysis on ICS using PPD or culture
ﬁltrate protein-10 (CFP10) as stimulating antigen were also
performed.2.6. Statistical analysis
In this study, the sample size calculation was not based on any
objective or endpoint. Nevertheless, the pre-speciﬁed sample size
of 80 adults in each cohort (40 receiving M72/AS01E, 40 receiving
the placebo) was appropriate to perform an initial evaluation of the
safety proﬁle and immunogenicity of the M72/AS01E vaccine in
each cohort. Since recruitment of participants in the TB-treated and
TB-treatment cohorts was stopped prematurely, the pre-deﬁned
sample size was not reached in these groups.
The primary safety analysis was based on the total vaccinated
cohort (TVC), which included all participants with at least one
vaccine administration documented. Immunogenicity analysis was
performed on the according to protocol (ATP) cohort, i.e., all
vaccinated and eligible participants, complying with protocol
deﬁned procedures, with no elimination criteria and for whom data
concerning immunogenicity endpoint measures were available.
The percentages of doses followed by solicited AEs (overall,
grade 3, and vaccine-related), and the percentages of participants
reporting unsolicited AEs classiﬁed by the Medical Dictionary for
Regulatory Activities (MedDRA)-preferred termwere assessed with
exact 95% conﬁdence intervals (CIs). Any reported SAEs were
described. Biochemical and haematological values outside of pre-
deﬁned reference ranges were recorded and assessed for clinical
signiﬁcance.
Geometric mean concentration (GMC) calculations were per-
formed by taking the anti-log of the mean of the log concentration
transformations. Antibody concentrations below the cut-off of the
assay were given an arbitrary value of half the cut-off for the pur-
pose of GMC calculation. M72-speciﬁc antibody seropositivity rates
and GMCs were calculated with 95% CIs.
Descriptive statistics of the frequency of M72-speciﬁc CD4þ/
CD8þ T-cells per million cells expressing 2 different immune
markers or any combination of immunemarkers were performed at
each timepoint.
Statistical analyseswere performed using the Statistical Analysis
System (SAS) version 8.2.3. Results
3.1. Characteristics of the study participants
In this study, 71 adults were vaccinated with the M72/AS01E
vaccine and 71 adults received the saline placebo. A total of 80
adults were included in the TB-naïve cohort, 49 in TB-treated
cohort, and 13 in the TB-treatment cohort. Recruitment of pa-
tients in the TB-treated and TB-treatment cohorts was stopped
prematurely in December 2013 following assessment of the post-
dose 2 available safety information in the TB-treatment sub-
cohort. At that time, the majority of participants in each group
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follow-upwas completed as planned, i.e. until 210 days post-dose 1.
All participants completed the study, except 1 participant from
the M72/AS01E group (consent withdrawal) and 1 participant from
the placebo group (lost to follow-up) in the TB-treatment cohort,
and 2 participants from the M72/AS01E group (consent withdrawal
and lost to follow-up) in the TB-treated cohort. For the M72/AS01E
group, the ATP cohort for immunogenicity included 7 participants
in the TB-treatment cohort, 21 participants in the TB-treated cohort
(3 excluded: randomisation code broken [n¼ 1] and administration
of only 1 dose of vaccine [n ¼ 2]), and 38 participants in the TB-
naïve cohort (2 excluded: non-compliance with blood sampling
schedule and administration of only 1 dose of vaccine).
Since enrolment started in Taiwan, all participants from the TB-
naïve cohort were from Asiane East Asian heritage; their mean age
was 33.8 and 33.3 years in the M72/AS01E and placebo groups,
respectively (Table 1). In the TB-treated and TB-treatment cohorts,
enrolment started in Taiwan, and Estonian trial sites were added to
increase recruitment; 54.2e83.3% of participants were fromWhite-
Caucasian/European heritage, and their mean age ranged from 42.9
to 47.0 years. Previous BCG vaccination or BCG scar was reported by
all participants in the TB-naïve cohort, and by 80.0% of partici-
pants in the other cohorts.
3.2. Safety
The most frequent solicited local AE (overall per dose) was pain,
which was reported after a maximum of 84.6%, 18.2%, 88.9%, 6.0%,
93.7% and 13.9% of doses in the TB-treatment-M72/AS01E, TB-
treatment-placebo, TB-treated-M72/AS01E, TB-treated-placebo,
TB-naïve-M72/AS01E, and TB-naïve-placebo groups, respectively
(Figure 1). Myalgia, fatigue, malaise, and headache were the most
frequently reported general AEs during the 7-day follow-up period
following M72/AS01E vaccination (Figure 2).
In the TB-treatment cohort, 3/11 participants who had received
a second dose of M72/AS01E experienced local swelling and/or
redness >50 mm, and 2 of them had swelling or redness >100 mm
during the 7-day follow-up period post-dose 2 (Table 2). These local
symptoms were limited in time, most had resolved or were
resolving after 6 days, and no speciﬁc diagnostic or therapeutic
interventions were triggered. An unscheduled unblinded safety
assessment during the enrolment phase was prompted by the
unexpected higher incidence of swelling >100 mm among partic-
ipants who had received a second dose of M72/AS01E in the TB-
treatment cohort (2/6; 33.3% [95% CI: 4.3e77.7%]) compared to
the TB-treated (1/21; 4.8% [95% CI: 0.1e23.8%]) and TB-naïve (1/39;
2.6% [95% CI: 0.1e13.5%]) cohorts. After in depth review of the
unblinded safety data by the sponsor, the study recruitment andTable 1
Baseline characteristics of the study participants and number of doses administered (tot
Parameter or category TB-treatment TB
M72/AS01E (N ¼ 7) Placebo (N ¼ 6) M7
Mean age (SD) 42.9 (11.5) 44.7 (11.8) 44
Female, n (%) 1 (14.3) 2 (33.3) 13
Race, n (%)
Asian e East Asian heritage 3 (42.9) 1 (16.7) 11
White e Caucasian/European heritage 4 (57.1) 5 (83.3) 13
Number of vaccine doses received, n (%)
1 1 (14.3) 1 (16.7) 2 (
2 6 (85.7) 5 (83.3) 22
Previous BCG vaccination or BCG scar 6 (85.7) 6 (100) 22
Footnote: TB-treatment ¼ adults receiving treatment for TB disease who have complet
successfully treated pulmonary TB disease; TB-naïve ¼ adults who never had TB; BCG ¼
(percentage) of participants in a given category; SD ¼ standard deviation; TB ¼ tubercufurther vaccination was terminated (Table 2). The 3 participants
from the TB-treatment cohort with post-dose 2 swelling/redness
>50 mm were from the same Estonian centre. One of the partici-
pants with swelling and redness >100mm also experienced fatigue
and headache with grade 2 intensity and fever (38.9 C) the day
after the second dose of study treatment, and also had redness and
swelling >50 mm during 3 days after the ﬁrst dose of study treat-
ment. No AEs suggestive of pulmonary pathology were observed
among the patients who had the very large local injection site re-
actions (>100 mm).
The proportion of doses followed by at least 1 unsolicited
symptom during 30 days post-vaccination was 7.7% (95% CI:
0.2e36.0%) in the M72/AS01E and 18.2% (95% CI: 2.3e51.8%) in the
placebo group of the TB-treatment cohort, 43.5% (95% CI:
28.9e58.9%) in the M72/AS01E and 14.0% (95% CI: 5.8e26.7%) in the
placebo group of the TB-treated cohort, and 25.3% (95% CI:
16.2e36.4%) in the M72/AS01E and 11.4% (95% CI: 5.3e20.5%) in the
placebo group of the TB-naïve cohort.
SAEs were reported by 2 participants in the M72/AS01E group
(hypersensitivity reaction and urinary calculi), 2 participants in
the placebo group (pneumonia, and ureteric calculi with hydro-
nephrosis) of the TB-treated cohort and by 1 participant in the
M72/AS01E group (anal ﬁstula and haemorrhoids) of the TB-naïve
cohort. One SAE was considered by the investigator as possibly
related to vaccination: a female from the M72/AS01E group in the
TB-treated cohort reported a grade 3 hypersensitivity reaction
(injection site reaction and fever) on the day after second dose of
study treatment, which was resolved after 9 days. The investi-
gator followed proactively this woman and provided further in-
formation on her condition to GSK Vaccines, according to the
protocol.
Although a few transient increases in liver function tests
(transaminases and/or bilirubin) were observed, no clear patterns
of vaccine-induced anomalies emerged.
3.3. Immunogenicity
3.3.1. Humoral immune response
Almost all participants (94.9%) in all the cohorts and groups
were seronegative at pre-vaccination (Table 3).
In participants of the M72/AS01E group, within each cohort,
seropositivity rates were 68.4% at 1 month post-dose 1, and
94.7% at 1 and 6 months post-dose 2. In the 3 cohorts, the ﬁrst
dose of the M72/AS01E vaccine induced a signiﬁcant increase in
M72-speciﬁc antibody GMCs, with further increase following
administration of the second dose (Figure 3).
No increase in M72-speciﬁc antibody GMCs was observed in
participants from the 3 cohorts who received placebo.al vaccinated cohort).
-treated TB-naïve
2/AS01E (N ¼ 24) Placebo (N ¼ 25) M72/AS01E (N ¼ 40) Placebo (N ¼ 40)
.5 (10.3) 47.0 (9.8) 33.8 (8.5) 33.3 (9.8)
(54.2) 7 (28.0) 16 (40.0) 21 (52.5)
(45.8) 11 (44.0) 40 (100) 40 (100)
(54.2) 14 (56.0) 0 (0.0) 0 (0.0)
8.3) 0 (0.0) 1 (2.5) 1 (2.5)
(91.7) 25 (100) 39 (97.5) 39 (97.5)
(91.7) 20 (80.0) 40 (100) 40 (100)
ed the intensive phase of treatment; TB-treated ¼ adults with previous history of
Bacille Calmette-Guerin; N ¼ total number of participants; n (%) ¼ total number
losis.
Figure 1. Overall per dose incidence of local symptoms (total vaccinated cohort). Footnote: TB-trt ¼ TB-treatment ¼ adults receiving treatment for TB disease who have completed
the intensive phase of treatment; TB-trted ¼ TB-treated ¼ adults with previous history of successfully treated pulmonary TB disease; TB-naïve ¼ adults who never had TB;
TB ¼ tuberculosis. Error bars represent 95% conﬁdence intervals.
Figure 2. Overall per dose incidence of general symptoms (total vaccinated cohort). Footnote: TB-trt ¼ TB-treatment ¼ adults receiving treatment for TB disease who have
completed the intensive phase of treatment; TB-trted ¼ TB-treated ¼ adults with previous history of successfully treated pulmonary TB disease; TB-naïve ¼ adults who never had
TB; TB ¼ tuberculosis. Error bars represent 95% conﬁdence intervals.
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The vaccine-induced M72-speciﬁc CD4þ T-cell responses were
evaluated by ﬂow cytometry and intracellular cytokine staining to
detect CD4þ T-cells expressing 2 immune markers among IFN-g,
IL-2, TNF-a, CD40L, IL-17 and IL-13. Since this study was terminatedbefore the end of the enrolment, the CMI analyses were performed
on a low number of available samples and should be interpreted
with caution. At pre-vaccination, low levels of M72-speciﬁc CD4þ T-
cells expressing 2 immune markers among IFN-g, IL-2, TNF-a,
CD40L, IL-17 and IL-13 were detected (frequency ranged from 68 to
Table 2
Local reactogenicity by dose in the TB-treatment and TB-treated cohorts (total vaccinated cohort).
Symptom
Type TB-treatment TB-treated
M72/AS01E Placebo M72/AS01E Placebo
N n % (95% CI) N n % (95% CI) N n % (95% CI) N n % (95% CI)
Dose 1
Pain All 7 6 85.7 (42.1, 99.6) 6 1 16.7 (0.4, 64.1) 24 21 87.5 (67.6, 97.3) 25 2 8.0 (1.0, 26.0)
Grade 2 7 0 0.0 (0.0, 41.0) 6 0 0.0 (0.0, 45.9) 24 12 50.0 (29.1, 70.9) 25 1 4.0 (0.1, 20.4)
Grade 3 7 0 0.0 (0.0, 41.0) 6 0 0.0 (0.0, 45.9) 24 3 12.5 (2.7, 32.4) 25 0 0.0 (0.0, 13.7)
Redness (mm) All 7 2 28.6 (3.7, 71.0) 6 0 0.0 (0.0, 45.9) 24 4 16.7 (4.7, 37.4) 25 0 0.0 (0.0, 13.7)
>50 7 1 14.3 (0.4, 57.9) 6 0 0.0 (0.0, 45.9) 24 4 16.7 (4.7, 37.4) 25 0 0.0 (0.0, 13.7)
>100 7 0 0.0 (0.0, 41.0) 6 0 0.0 (0.0, 45.9) 24 2 8.3 (1.0, 27.0) 25 0 0.0 (0.0, 13.7)
Swelling (mm) All 7 2 28.6 (3.7, 71.0) 6 0 0.0 (0.0, 45.9) 24 5 20.8 (7.1, 42.2) 25 1 4.0 (0.1, 20.4)
>50 7 1 14.3 (0.4, 57.9) 6 0 0.0 (0.0, 45.9) 24 3 12.5 (2.7, 32.4) 25 1 4.0 (0.1, 20.4)
>100 7 0 0.0 (0.0, 41.0) 6 0 0.0 (0.0, 45.9) 24 1 4.2 (0.1, 21.1) 25 0 0.0 (0.0, 13.7)
Dose 2
Pain All 6 5 83.3 (35.9, 99.6) 5 1 20.0 (0.5, 71.6) 21 19 90.5 (69.6, 98.8) 25 1 4.0 (0.1, 20.4)
Grade 2 6 3 50.0 (11.8, 88.2) 5 1 20.0 (0.5, 71.6) 21 14 66.7 (43.0, 85.4) 25 0 0.0 (0.0, 13.7)
Grade 3 6 0 0.0 (0.0, 45.9) 5 0 0.0 (0.0, 52.2) 21 5 23.8 (8.2, 47.2) 25 0 0.0 (0.0, 13.7)
Redness (mm) All 6 3 50.0 (11.8, 88.2) 5 0 0.0 (0.0, 52.2) 21 7 33.3 (14.6, 57.0) 25 0 0.0 (0.0, 13.7)
>50 6 3 50.0 (11.8, 88.2) 5 0 0.0 (0.0, 52.2) 21 4 19.0 (5.4, 41.9) 25 0 0.0 (0.0, 13.7)
>100 6 2 33.3 (4.3, 77.7) 5 0 0.0 (0.0, 52.2) 21 2 9.5 (1.2, 30.4) 25 0 0.0 (0.0, 13.7)
Swelling (mm) All 6 3 50.0 (11.8, 88.2) 5 0 0.0 (0.0, 52.2) 21 4 19.0 (5.4, 41.9) 25 0 0.0 (0.0, 13.7)
>50 6 2 33.3 (4.3, 77.7) 5 0 0.0 (0.0, 52.2) 21 3 14.3 (3.0, 36.3) 25 0 0.0 (0.0, 13.7)
>100 6 2 33.3 (4.3, 77.7) 5 0 0.0 (0.0, 52.2) 21 1 4.8 (0.1, 23.8) 25 0 0.0 (0.0, 13.7)
Footnote: TB-treatment ¼ adults receiving treatment for TB disease who have completed the intensive phase of treatment; TB-treated ¼ adults with previous history of
successfully treated pulmonary TB disease; N ¼ total number of participants; n (%) ¼ total number (percentage) of participants in a given category; CI ¼ conﬁdence interval;
TB¼ tuberculosis; Grade 2 pain: Painful when limb was moved and interfered with every day activities; Grade 3 pain: Signiﬁcant pain at rest that prevented normal every day
activities.
Table 3
Seropositivity rates and GMCs for M72-speciﬁc antibodies measured by ELISA (ATP immunogenicity cohort).
Timepoint TB-treatment TB-treated TB-naïve
M72/AS01E (N ¼ 7) Placebo (N ¼ 6) M72/AS01E (N ¼ 24) Placebo (N ¼ 25) M72/AS01E (N ¼ 40) Placebo (N ¼ 40)
N ≥ 2.8 EU/ml %
(95% CI)
N ≥ 2.8 EU/ml %
(95% CI)
N ≥ 2.8 EU/ml %
(95% CI)
N ≥ 2.8 EU/ml %
(95% CI)
N ≥ 2.8 EU/ml %
(95% CI)
N ≥ 2.8 EU/ml %
(95% CI)
Pre 7 0.0 (0.0, 41.0) 4 0.0 (0.0, 60.2) 21 0.0 (0.0, 16.1) 25 0.0 (0.0, 13.7) 37 2.7 (0.1, 14.2) 39 5.1 (0.6, 17.3)
Day 30 6 83.3 (35.9, 99.6) 4 0.0 (0.0, 60.2) 21 90.5 (69.6, 98.8) 25 0.0 (0.0, 13.7) 38 68.4 (51.3, 82.5) 39 5.1 (0.6, 17.3)
Day 60 6 100 (54.1, 100) 3 0.0 (0.0, 70.8) 19 94.7 (74.0, 99.9) 25 0.0 (0.0, 13.7) 38 97.4 (86.2, 99.9) 39 7.7 (1.6, 20.9)
Day 210 6 100 (54.1, 100) 3 0.0 (0.0, 70.8) 19 94.7 (74.0, 99.9) 25 0.0 (0.0, 13.7) 38 100 (90.7, 100) 39 2.6 (0.1, 13.5)
N GMC (95% CI) N GMC (95% CI) N GMC (95% CI) N GMC (95% CI) N GMC (95% CI) N GMC (95% CI)
Pre 7 1.4 (1.4, 1.4) 4 1.4 (1.4, 1.4) 21 1.4 (1.4, 1.4) 25 1.4 (1.4, 1.4) 37 1.4 (1.4, 1.5) 39 1.5 (1.4, 1.6)
Day 30 6 6.7 (2.1, 21.0) 4 1.4 (1.4, 1.4) 21 11.7 (6.3, 22.0) 25 1.4 (1.4, 1.4) 38 4.5 (3.3, 6.2) 39 1.5 (1.4, 1.6)
Day 60 6 206.6 (46.2, 923.2) 3 1.4 (1.4, 1.4) 19 226.2 (99.0, 517.2) 25 1.4 (1.4, 1.4) 38 248.6 (171.0, 361.4) 39 1.7 (1.3, 2.3)
Day 210 6 38.4 (18.9, 77.9) 3 1.4 (1.4, 1.4) 19 50.9 (27.3, 94.8) 25 1.4 (1.4, 1.4) 38 45.6 (34.2, 60.8) 39 1.4 (1.4, 1.5)
Footnote: TB-treatment ¼ adults receiving treatment for TB disease who have completed the intensive phase of treatment; TB-treated ¼ adults with previous history of
successfully treated pulmonary TB disease; TB-naïve ¼ adults who never had TB; ATP ¼ according-to-protocol; ELISA ¼ enzyme linked immunosorbent assay; EU/ml ¼ ELISA
units per millilitre; N ¼ total number of participants; % ¼ percentage of participants with titres above the speciﬁed cut-off; CI ¼ conﬁdence interval; GMC ¼ geometric mean
concentration; TB ¼ tuberculosis.
P. Gillard et al. / Tuberculosis 100 (2016) 118e127 1234544 per million cells). After the ﬁrst dose of the M72/AS01E vac-
cine, an increased frequency of M72-speciﬁc CD4þ T-cells was
identiﬁed after in vitro stimulation. The second dose of the M72/
AS01E vaccine induced a further increase of this M72-speciﬁc CD4þ
T-cell response, which persisted at signiﬁcantly higher magnitude
than at pre-vaccination during the 6-month follow-up period
(Figure 4). The frequencies of CD4þ T-cells expressing IL-17 or IL-13
upon in vitro stimulation with M72 were low (data not shown).
Although the number of participants was too low to draw robust
conclusions, the frequency of polyfunctional M72-speciﬁc CD4þ T-
cells expressing any combination of immunemarkers among IFN-g,
IL-2, TNF-a and CD40L seemed to be higher in the TB-treatment and
TB-treated cohorts than in the TB-naïve cohort (Supplement 1).
These polyfunctional CD4þ T-cells comprised predominantly
CD40Lþ TNF-aþ IFN-gþ, CD40Lþ IL-2þ TNF-aþ IFN-gþ and CD40Lþ
IFN-gþ expression proﬁles. The frequency of CD4þ T-cells express-
ing only CD40L or IFN-g seemed higher in the TB-naïve cohort.
The PPD- and CFP10-speciﬁc CD4þ T-cell responses were at
similar levels at pre- and post-vaccination for each combination ofimmune markers, and no vaccine-induced responses to these
mycobacterial antigens were detected by ICS. M72-, PPD-, and
CFP10-speciﬁc CD8þ T-cell responses were low and did not increase
signiﬁcantly over time in M72/AS01E recipients. No M72-speciﬁc
CD4þ and CD8þ T-cell responses were observed in the partici-
pants who received the placebo (data not shown).
Exploratory analyses, which were incorporated in the statis-
tical analysis plan before the full unblinding of the study, were
performed to compare the vaccine-induced immune responses in
participants without, and with grade 1, 2 and 3 local symptoms,
but no conclusions could be drawn due to the low number of
data.
4. Discussion
In this study, the safety, reactogenicity, and immunogenicity of
the M72/AS01E vaccine were compared for the ﬁrst time in adults
treated for TB disease who had completed the intensive phase of
treatment and adults with a history of treatment for TB disease.
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Figure 3. Evolution of M72-speciﬁc antibody GMCs for the M72/AS01E group within
each cohort (ATP cohort for immunogenicity). Footnote: TB-trt ¼ TB-
treatment ¼ adults receiving treatment for TB disease who have completed the
intensive phase of treatment; TB-trted ¼ TB-treated ¼ adults with previous history of
successfully treated pulmonary TB disease; TB-naïve ¼ adults who never had TB;
ATP ¼ according-to-protocol; EU/ml ¼ ELISA units per millilitre; GMC ¼ geometric
mean concentration; TB ¼ tuberculosis. Error bars represent exact 95% conﬁdence
intervals. X give the individual results for the participants with post-dose 2 swelling
>100 mm. Of note, crosses are presented for the participant from the TB-trted cohort
with post-dose 2 swelling >100 mm, but this participant was excluded from the ATP
cohort for immunogenicity.
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Figure 4. Frequency of M72-speciﬁc CD4þ T-cells expressing at least 2 immune markers am
group within each cohort (ATP cohort for immunogenicity). Footnote: TB-trt ¼ TB-treatment
treatment; TB-trted ¼ TB-treated ¼ adults with previous history of successfully treated pulm
N ¼ number of samples; TB ¼ tuberculosis; PI ¼ post-dose 1; PII ¼ post-dose 2; CD40L ¼ C
factor alpha; IL-13 ¼ interleukin 13; IL-17 ¼ interleukin 17. The boxplot: the central box sh
median (Q2), and the whiskers (above and below the box), the maximum and the minim
swelling >100 mm. Of note, crosses are presented for the participant from the TB-trted coho
cohort for immunogenicity.
P. Gillard et al. / Tuberculosis 100 (2016) 118e127124Following administration of the second dose of blinded vaccine, a
high incidence of self-resolving grade 3 local symptoms was
observed at the injection site in participants undergoing TB treat-
ment (2/11 participants had swelling or redness with a diameter of
>100 mm). These skin reactions were limited in time and resolved
without sequelae. Swelling with grade 3 intensity was more
frequently reported in the participants being treated for TB disease
compared with the 2 other cohorts. Due to these unexplained local
reactions, further recruitment and vaccination in this study was
discontinued. No additional clinically relevant AEs or AEs sugges-
tive of pulmonary pathology were observed. Although a SAE
considered as possibly related to vaccination was reported in a
woman from the TB-treated cohort (hypersensitivity reaction on
the day of administration of the second dose of M72/AS01E), this
did not appear to be linked to pulmonary TB. The safety signal could
not be explained either by the available preclinical data (results not
shown), clinical data, demographic characteristics, or humoral or
cellular immune responses for the proposed study timepoints.
Other analyses would be required to determine if the high skin
reactogenicity might be correlated with immune responses at
earlier timepoints following vaccination or if it could be explained
by differences in gene expression (microarray analysis) or any other
markers.
Recent insights into the mode of action of AS01 indicate that the
adjuvant effect of AS01 is limited in time and is associated with a
local inﬂammatory response at the injection site and draining
lymph node [20]. This response is characterized by a transientipants with samples available
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PII(D37) PII(D60) PII(D210)
ong IL-2, IFN-g, TNF-a, CD40-L, IL-17 and IL-13 for each timepoint in the M72/AS01E
¼ adults receiving treatment for TB disease who have completed the intensive phase of
onary TB disease; TB-naïve ¼ adults who never had TB; ATP ¼ according-to-protocol;
D40-ligand; IFN-g ¼ interferon gamma; IL-2 ¼ interleukin 2; TNF-a ¼ tumor necrosis
ows the interquartile range (Q1eQ3), with the thick horizontal line representing the
um. X give the individual results that are available for participants with post-dose 2
rt with post-dose 2 swelling >100 mm, but this participant was excluded from the ATP
P. Gillard et al. / Tuberculosis 100 (2016) 118e127 125induction of cytokines and the local recruitment and activation of
innate cells, which may provide explanations for the local reac-
togenicity proﬁle associated with the AS01-containing candidate
vaccines. Extensive preclinical studies for various vaccine antigens
in combination with AS01 did not demonstrate local or systemic
effects due to the vaccination, other than mild local injection site
reactions. In addition, large local injection site reactions have not
been typically observed in clinical studies evaluating several
candidate AS01-containing vaccines [21,22]. Injection-site symp-
toms are typically mild to moderate, transient and of short duration
and have not affected compliance with the vaccination schedules.
In a mouse model, AS01 has been shown to induce a rapid and
transient innate immune response at the injection site, including
both cytokine production and innate immune cell recruitment [20].
Neutrophils and monocytes, which are well known to contribute to
local inﬂammation [23], were the main immune population
recruited at the injection site. Cytokines detected at the injection
site included many mediators of local inﬂammation, such as IFN-g,
IL-6 and granulocyte colony-stimulating factor (GCSF), although
others, such as TNF-a or IL-1b, were only detected at minimal
levels. This innate immune activation peaked at 24 h post-
immunisation and had completely waned by 7 days after immu-
nisation. Additionally, INF-g was detected one day after immuni-
sation in the serum of individuals vaccinated with the M72/AS01E
vaccine [11] and in individuals vaccinatedwith an AS01-adjuvanted
hepatitis B vaccine [24], suggesting an early activation of the im-
mune system after vaccination. In both studies, the level of IFN-g in
the serum was much higher after the second dose of vaccine than
after the ﬁrst one, suggesting a role for pre-existing immunity in
promoting early responses to vaccination. In a study on a smallpox
vaccine, reactogenicity following vaccination was also correlated to
some pro-inﬂammatory cytokines, including IFN-g [25]. Although
the M72/AS01E vaccine induced IFN-g in the present study, no
pattern of increased peripheral CD4þ/CD8þ T-cell response were
distinguished that may be associated with the high skin
reactogenicity.
Large local injection site reactions have not been typically
observed with other M. tuberculosis vaccine antigens either. The
intradermal administration of the Modiﬁed Vaccinia virus Ankara
(MVA85A), which expresses the highly conserved M. tuberculosis
antigen 85A, was associated with local injection-site reactions
(erythema, swelling and other mild local skin reactions) in healthy
and HIV-infected adults [26e28]._ENREF_17 Dose-dependent local
adverse reactions were also observed in BCG-naïve healthy adults
following subcutaneous administration of a therapeutic vaccine
consisting of detoxiﬁed liposomal fragments of M. tuberculosis
(RUTI®, Archivel Farma S.L.) [29]. Previous studies also showed that
mild to moderate local AEs were frequent following administration
of a vaccine consisting of a replication-deﬁcient adenovirus vector
containing the M. tuberculosis antigens 85A, 85B and TB10 (Crucell
Ad35/Aeras 402) [27,30,31].
Although this was not conﬁrmed, one possible explanation for
the large local injection site reactions observed in patients treated
for TB disease could be related to the prior sensitisation to myco-
bacterial antigens. Although no necrosis at the injection site was
observed in our study, themechanism responsible for the increased
reactogenicity may be resembling that of the Shwartzman re-
actions. These reactions were previously observed in
M. tuberculosis-infected mice that developed cutaneous necrosis at
a site of a previous endotoxin injection after intravenous injection
of lipopolysaccharides similar to mycobacterial antigens [32e35].
In Shwartzman reactions, the initial skin inﬂammation causes
endothelial activation and accumulation of inﬂammatory cells, and
a subsequent cytokine-inducing signal triggers necrosis. The
increased reactogenicity could also be caused by an extreme formof delayed hypersensitivity, similar to previously reported exag-
gerated reactions to the Mantoux test [36,37]. In contrast, the
increased reactogenicity was unlikely to be due to Koch reactions,
which correspond to disease exacerbations in M. tuberculosis-
infected individuals upon newly exposure to mycobacterial com-
pounds [33,38]. Although the immunological mechanism behind
the Koch phenomenon is not known, the absence of AEs suggestive
of pulmonary pathology indicated that the vaccine did not induce
lung inﬂammation and that Koch reactions did not lie behind the
large, self-resolving (without sequel) skin reactions in TB-infected
patients [39]. Antigen dose or antigen/adjuvant dose ratios could
also account for the observed large injection site reactions, as
previously seen in studies on other non-TB adjuvanted candidate
vaccines where the largest antigen dosage resulted in the highest
transient local reactogenicity [40,41].
In line with results of previous studies, the M72/AS01E vaccine
was immunogenic and induced robust humoral antibody re-
sponses in the 3 cohorts. The M72/AS01E vaccine induced also a
robust M72-speciﬁc CD4þ T-cell response, which displayed a Th1
polyfunctional phenotype [11,42]. Although no immune correlates
of protection against TB have been deﬁned, IFN-g, TNF-a, IL-2, and
IL-17 are important for the control of mycobacterial infection
[43e47]._ENREF_36 The peripheral CD4þ T-cell responses seemed
lower after the ﬁrst dose of the M72/AS01E vaccine in the TB-naïve
cohort compared with the other cohorts. Moreover, in M72/AS01E
recipients from the TB-naïve cohort, a trend for a lower poly-
functionality level of CD4þ T-cells and a higher proportion of CD4þ
T-cells only expressing CD40L were observed. This ﬁnding sup-
ports the expansion of functionally distinct T-cells in populations
primed by natural mycobacterial infection [12,13]. In line with
previous observations, almost no IL-13- and very low levels of IL-
17-expressing CD4þ T-cells were detected [42]. The amplitude of
the observed M72-speciﬁc CD8þ T-cell responses in PBMC was
low, in line with previous studies on M72 candidate vaccines
[11,42].
This study was limited by _ENREF_36 the small sample size in
the TB-treatment cohort, which precluded deﬁnitive conclusions to
be drawn about the safety and immunogenicity results. Other
limitations include the small number of samples available for CMI
analyses, and the lack of samples (serum or PBMC) taken at early
timepoints post-vaccination. Since this study was terminated
before the end of the enrolment for safety reasons, we could not
draw conclusions regarding the evaluation of the M72/AS01E vac-
cine in the TB-treatment cohort, but the sample size was adequate
for descriptive endpoints in the TB-treated and TB-naïve cohorts.
Since all analyses were exploratory and not corrected for multi-
plicity, and the sample size was too small to have the power to
detect a speciﬁc difference based on non-overlapping 95% conﬁ-
dence intervals; therefore, we should be cautious while interpret-
ing the results of this study and their clinical relevance should be
assessed in future studies.5. Conclusions
In adults previously or currently treated for TB disease, 2 doses
of the M72/AS01E vaccine induced high M72-speciﬁc antibody
levels and robust M72-speciﬁc Th1 cytokine-producing CD4þ T-cell
responses. In the present study, recruitment ended prematurely
because of a high incidence of large local injection site redness/
swelling reactions in M72/AS01E-vaccinated adults undergoing TB-
treatment; further analyses are required to explain this high local
reactogenicity. No additional clinically relevant AEs were observed,
except one possibly vaccine-related SAE (hypersensitivity in TB-
treated-M72/AS01E).
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